[Clinical-physiological characteristics and hormone therapy of patients with typical form of climacteric syndrome]. / Kliniko-fiziologicheskaia kharakteristika i gormonoterapiia bol'nykh s tipichnoi formoi klimaktericheskogo sindroma.

Clinical and physiological examinations of 76 women in the postmenopause revealed in 64 of them the typical form of the climacteric syndrome, characterized by not only typical symptoms ("flushes", increased exudation, headaches, etc.), but also by various emotional vegetative disturbances detected at profound clinical neurological examination of the autonomic nervous system and the emotional sphere. Individual hormone therapy was associated with an appreciable alleviation of all psychovegetative disorders: "flushes", exudation, irritability, arterial hypertension, severity of vegetative dystonia, hysterical stigmata.

[Clinical data on the use of current oral contraceptives]. / Klinicheskie dannye primeneniia sovremennykh oral'nykh kontratseptivov.

PIP: The effectiveness and safety of 3 Hungarian 2nd and 3rd generation oral contraceptives (OCs) were studied. The study included 225 healthy women aged 18-40. 70 women were taking Ovidan, a 2nd generation combination OC that contains 50 mcg of ethinyl estradiol and 250 mcg of d-norgestrel. None of the women became pregnant in 562 menstrual cycles. Side effects were recorded in 32.8% of the cases, 37.4% with other combination OCs. 100 women were given Rigevidon--a 3rd generation combination OC with minimum doses of estrogenic and gestagenic components (30 mcg of ethinyl estradiol and 150 mcg of d-norgestrel). This preparation was 100% effective, while the occurrence of side effects (29%) was even lower than with Ovidan. 55 women took Postinor, a gestagenic postcoital OC containing .75 mg of d-norgestrel in each pill. The preparation was 100% effective. 20 women developed metrorrhagic hemorrhages; in 4 patients, menstrual delay was observed. Postinor, as a highly effective gestagenic agent, can also be used in the treatment of various gynecological disorders. Based on these results and the data available in the literature, wider application of Ovidan, Rigevidon, and Postinor for oral contraception and therapy is strongly recommended.^ieng